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Summary Serum samples from a biological serum bank taken several years before the diagnosis of cancer,
were analysed for S-Tg and S-TSH in 43 patients with thyroid cancer and compared to 128 healthy controls
matched for age, sex, geographical region and time of blood sampling.
The main finding was the difference in S-Tg between cases and controls, the highest values being found in
sera from cases. Relative risk of thyroid cancer increases with increasing S-Tg levels (the global test giving
P<0.0005). Extremely high levels were found in 4 cases with follicular and 3 with anaplastic cancers. No such
statistically significant difference was found in S-TSH concentration. Possible explanations for the elevated
S-Tg observed several years before clinically evident malignant tumour are discussed.
In 1985 a multidisciplinary study on the aetiology of thyroid
cancer was set up in Norway. The main target was the high
incidence of this type of cancer in fishing communities in
northern Norway (Thoresen et al., 1986), supporting the
hypothesis that excess intake of iodide may be a carcinogenic
factor for papillary adenocarcinoma of the thyroid gland
(Williams et al., 1977). As another line of investigation, we
studied possible pathobiological mechanisms in the thyroid
gland before the clinical appearance of tumour at a time
when the organ is probably exposed to carcinogenic factors
and accordingly under some kind of biological stress.
This study was made possible by matching persons with
blood samples in a biological serum bank containing 300,000
sera from 100,000 Norwegians (Janus) with the nationwide
Cancer Registry ofNorway. By the end of 1985 2,500 persons
in the serum bank had developed cancer. Among these were
47 subjects with a malignant tumour. To detect possible
biological stress, perturbations in thyroglobulin (S-Tg) and
thyroid-stimulating hormone (S-TSH) levels in sera taken
several years before clinical appearance of tumour were
measured. The serum values in these future cancer patients
were compared to those of matched, healthy controls, in
which no cancer had occurred by the end of 1985.
Accordingly, the design of the investigation was that of a
case control study.
Thyroglobulin is a large glycoprotein produced by the
follicular cells in the thyroid gland. Due to the widespread
use of radioimmunoassay for S-Tg, there have been several
reports on the role of S-Tg in the follow-up of patients with
thyroid cancer (Girelli et al., 1985). It has been remarked by
several authors that the S-Tg levels are dependent on histo-
logical types, medullary and anaplastic having normal or
very low values (Pacini et al., 1980). It has also been claimed
that S-Tg is of no value in the initial diagnosis of thyroid
cancer, since the test does not discriminate between benign
and malignant thyroid conditions (Pacini et al., 1980). Little
is, however, known about the role of thyroglobulin and
thyroid-stimulating hormone in the preclinical phase of
thyroid cancer.
S-TSH is not regarded as a tumour marker for thyroid
carcinoma, but continued stimulation with TSH is known to
increase the potential of thyrocarcinogenic compounds in the
animal model, as well as the growth of human differentiated
thyroid carcinomas once established. In previous epidemio-
logical studies of patients with thyroid carcinomas no
increase in S-TSH has been found. However, S-TSH has not
previously been measured with the ultrasensitive methods
now available. Thus possible increase in TSH stimulation
before diagnosis may have passed undetected.
The main purpose of this study was to analyse this
problem further, by comparing the apparently normal
thyroid gland in individuals who later developed cancer
(cases) with that of healthy persons (controls). Our
assumption was that this would be of importance for the
pathobiological understanding of carcinogenesis in this
organ.
Materials and methods
The registration of cancer cases has been compulsory in
Norway since 1953. Information concerning all cancer
patients is collected in the Cancer Registry of Norway. The
Janus collection is a serum bank consolidated from several
sources and maintained by the Norwegian Cancer Society
for research purposes (Jellum et al., 1986). The collection
includes sera from cohort studies on cardiovascular disease
conducted in 4 different counties in Norway. Up to 3
consecutive samples are available from each person. In
addition, specimens from more than 25,000 Red Cross blood
donors are continually being added to the collection, and
from 2 to 13 (average 4) consecutive samples are available
from each donor. The sera are stored at -.25°C. The earliest
specimens date from 1973 and about 100,000 persons had
made donations at the time of the present investigation. The
Janus collection has been matched with the files in the
Cancer Registry. Of a total of 2,500 cancer patients, 47 had
malignant thyroid tumours.
For each cancer patient 3 controls were selected from the
serum bank matched for sex, age (±3 years), calendar year
of blood-sampling and geographical region. Samples from
cases and controls were randomly numbered and distributed
for assay purposes and the code was not broken until all
analytical results were reported.
Histological review was undertaken on all slides, which
were classified according to the World Health Organisation
(WHO, 1982). Routine slides stained with haematoxylin and
eosin were used. One tumour was judged to be benign and
excluded from further studies. In addition we found one
cancer of the medullary type (S-Tg=0). As mentioned below
2 cases and 1 control with autoantibodies against S-Tg were
also excluded, leaving 43 cases (13 males; 30 females) and
128 corresponding controls for further studies.
Thyroglobulin measurements were performed with a
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commercial human thyroglobulin immunoradiometric assay
kit from Sorin, Saluggia, Italy. The detection limit, based
on studies with water banks, was <2pgl-1. S-Tg values in
patients after total thyroidectomy were <3 pgl- 1. The intra-
assay coefficient of variation (CV) was 3.9%, and inter-assay
CV was 7.2%, within the range 5-lOOgl 1
All sera were tested for thyroglobulin antibodies with a
commercial haemagglutination kit, 'Thymune-T' (Wellcome
Diagnostics, Dartford, U.K.). Sera containing autoantibodies
against thyroglobulin were excluded from the study.
TSH was measured with an ultrasensitive commercial
immunoradiometric assay 'Sucrosep TSH IRMA' (Boots
Celltech, Berkshire, U.K.) with a typical limit of detection
0.07mUl1- (zero standard+3 s.d.), normal range 0.1-
8.0mUl-1 (0-99.7 percentile), and inter-assay CV 6% at the
upper normal limit.
Cases and controls were allocated to a 2 x4 contingency
table according to level of S-Tg and relative risks for cases
versus controls computed. The global test for homogeneity, a
x2 test for trend, and 95% confidence intervals for the
relative risks (odds ratio) were calculated (Breslow & Day,
1980).
Results
The essential finding of the study was the difference in S-Tg
between cases and controls. In Table I both groups are
classified according to increasing S-Tg intervals (both sexes
combined). Twelve of 43 (28%) had S-Tg values
>lSOpgl-1, compared with only 3 out of 128 (2%)
controls. The difference between patients and controls in
Table I is statistically significant (P<0.0005) according to
the global test. Table I also shows that the odds ratio
increases with increasing S-Tg values. Although the figures
in some of the windows of the table are small, the conclusion
is that the higher odds ratios are significantly > 1 (P<0.05).
There is also a statistically significant (P<0.0005) upward
trend in the odds ratios with increasing S-Tg level.
The scatter-diagram in Figure 1 illustrates the S-Tg values
for all cases both sexes combined. The x-axis gives the time
between blood sampling and cancer diagnosis (interval-time).
Both high and low S-Tg values are scattered along the x-axis
without any distinct pattern, although there is a trend
(grouped data) toward higher values nearer tumour
presentation.
Of particular interest is the relation of histological type to
S-Tg level. Histological review of the material showed that
36 cases had papillary thyroid cancer, while 4 were of the
follicular type and 3 tumours were anaplastic. Figure 1
indicates that all the non-papillary types were associated
with relatively high S-Tg values, while only 7 of the 36
papillary tumours had this high level. Also of interest is the
high level of S-Tg in the 3 patients with anaplastic tumours.
Considering the S-Tg levels alone in the 36 cases with
papillary tumour and their corresponding controls, the odds
ratios increase with increasing S-Tg levels, and the global
test is significant (P<0.005).
Most of the cases were in the age group 40 to 55 years.
Age at diagnosis and age at time of blood sampling had no
influence on the level of S-Tg (Table II). The number of
cases with metastases at the time of diagnosis is listed in
Table III. The 3 anaplastic cases all had distant metastases
on admission to hospital. They all died within a few months.
In addition, one follicular and one papillary tumour had
distant metastases, which were fatal shortly afterwards. Five
of the papillary cases had lymph node metastases to the
neck, none of whom had died by June 1986.
Of the 43 patients 13 were males and 30 were females. In
Table IV the cases are grouped, each sex separately
according to increasing S-Tg concentration. Thirty-three
percent of the women had S-Tg values > 150 pg1- 1
compared to 15% of males. It is, however, important to
Table I Numbers of cases and controls grouped according to
increasing S-Tg values, both sexes combined
TG (pgl-1) Cases Controls Total Odds ratio
0-29 17 82 99 l
30-89 10 39 49 1.2
90-149 4 4 8 4.8
150- 12 3 15 19.3
Total 43 128 171
Global test X2=30.25 (df=3); Test for trend X2=28.81 (df= 1).
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Figure 1 S-Tg values (cases) grouped according to time between
blood sampling and cancer diagnosis (years), and histological
type. * papillary; A follicular; 0 anaplastic.
Table II Age at diagnosis grouped according
to sex and increasing S-Tg values
Age in years+s.d.
TG (gl1-) Men Women
0-29 47.1+ 10.3 46.7+ 5.8
30-89 54.4+ 14.8 46.6+8.4
90-149 41.0+ 4.0 41.9+5.8
150- 50.3+ 7.4 47.9+3.8
Table III Numbers of cases with and without nodal and distant
metastases grouped according to histological type. Numbers of
deaths in parentheses
Histological Lymph node Distant Without
type metastases metastases metastases Total
Papillary 5 1(1) 30 36
Follicular 0 1(1) 3 4
Anaplastic 0 3(3) 0 3
Total 5 5(5) 33 43
Table IV Numbers of cases grouped according
to sex and increasing S-Tg values
TG (ggl1-) Men Women Total
0-29 6 11 17
30-89 3 7 10
90-149 2 2 4
150- 2 10 12
Total 13 30 43
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emphasize that the normal upper limit by this method is
70jgI1 for males and 150 gI- I for females.
The cases had a mean S-TSH value =2.19+1.93,uml1
(range 0.0-12.0) compared to controls 2.24+2.36pmI-P
(range 0.4-19.4).
Discussion
The present investigation is a prospective study, designed as
a classical case control study with controls matched for sex,
age, time of blood sampling (year) and geographical region
in Norway. Matching for geographical region was done
because preliminary results indicated that S-Tg values show
different levels in different regions of Norway (Myking &
Unjem, 1983).
It was possible to accomplish this study solely because of
the unique Janus blood sample collection and its linkage to
the nationwide Cancer Registry of Norway. All slides have
been reviewed. The laboratory tests used are well established
and in clinical use as routine tests in patients with different
types of thyroid diseases (Black et al., 1981).
The essential finding of the present investigation is the
difference in S-Tg in blood samples between cases and
controls, which is highly significant.
To our knowledge, no reports have been published on the
level of S-Tg in the preclinical phase of thyroid cancer. At
diagnosis, but before therapy, other investigations have
reported that 43% (16/37) of patients with papillary
carcinomas and 81% (21/26) of patients with follicular
carcinomas have S-Tg elevation above the 97.5 percentile
(40,ugl-1) of the normal range (Refetoft & Lever, 1983).
There is general agreement that patients with anaplastic
carcinomas usually do not have S-Tg elevation (Pacini et al.,
1980; Black et al., 1981; Ericsson et al., 1984; Torriginai et
al., 1969; Basclueri et al., 1981), but such elevation can occur
(Feldt-Rasmussen et al., 1983; Bottger et al., 1980; Monaco
et al., 1983). We found that 25% (9/36) of cases with
papillary, 100% (4/4) with follicular and 100% (3/3) with
anaplastic carcinomas had S-Tg >90jugl- years before
cancer diagnosis. This shows that in papillary and follicular
carcinomas there is no fundamental change in S-Tg levels
from the preclinical to the clinical stage developing years
later.
With regard to the prolonged preclinical elevation of S-Tg,
this should be evaluated in conjunction with the lack of
difference in S-TSH between cases and controls. Whatever
the explanation for the elevated S-Tg in our cases, it is clear
that the gland has not been stressed or hyperactivated by
TSH during the period prior to diagnosis. Moreover, the
prolonged latency period from S-Tg elevation to clinical
tumour manifestation suggests a continued release from
dormant tumour cells rather than from destruction of
adjacent thyroid follicles being actively invaded by growing
tumour tissue. Altered histological architecture in a tumour
may be responsible for abnormal thyroglobulin release into
extracellular fluid and lymphatics, instead of the normal
storage in follicles. Autopsy studies have revealed that so-
called occult thyroid cancer is present in a high percentage
of subjects dying from other unrelated diseases (Christensen
et al., 1984). If, as we postulate, our cases have had very
small thyroid carcinomas several years before the tumours
became clinically apparent, then these small neoplasms must
be responsible for the relatively large leakage of S-Tg to
peripheral blood.
Of particular interest is our finding of high S-Tg in the 3
cases who later developed anaplastic carcinomas. This
suggests that for unknown reasons in some persons
progression occurs from a preclinical stage with differen-
tiated and slowly growing tumour cells producing thyro-
globulin, towards the dedifferentiated clinical stage with the
normalized S-Tg levels reported by others.
Our study does not offer any solution as to what is the
initiating factor(s) in thyroid cancer. S-Tg could be a clue. It
could be speculated that the early elevation of S-Tg is not a
tumour cell secretory product as such, but rather a leakage
phenomenon caused by some destructive carcinogenic factor.
Alternatively, S-Tg leakage might open the gland to the
influence of circulating carcinogens. Different pathological
conditions can apparently elevate S-Tg by a variety of
mechanisms (Refetoft & Lever, 1983).
Of the three controls (all females) who had S-Tg levels
above 150pgl-1, one was ultimately found to have
undergone surgery for simple goitre in 1956, another was to
be operated on for the same disease in the near future, and
the third was without any symptoms related to the thyroid
gland. Strictly speaking, the two women with non-malignant
thyroid disease should not have been included as controls, an
omission which would have made the difference between
cases and controls even more striking. On the other hand,
none of the other controls were examined for benign thyroid
diseases.
We conclude that S-Tg tends to be increased years before
the clinical appearance of thyroid carcinoma, whereas S-TSH
is not elevated. This implies that the initiating carcinogenic
factors do not act even partially, by inhibition of thyroid
hormone production, with secondary TSH stimulation
leading to tumour promotion and progression. Whether the
increased S-Tg is a secretory product from slowly growing
subclinical tumours or a leakage phenomenon from normal
follicles cannot be answered by our data. The frequency of
elevated S-Tg seems to be of the same magnitude in the
preclinical as in the early clinical stage of thyroid carcinoma.
Despite this, S-Tg determination has poor predictive value
as a screening test for thyroid malignancy, because of its
low specificity and the low prevalence of the disease.
Unexplained increased S-Tg values, however, should indicate
close follow-up of the patient.
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